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Abstract 
Mineralogical analyses of clinical samples have been proved useful to identify causal 
relationship between exposure to airborne particles and pulmonary diseases. However, this 
type of analyses only considers the micron-sized fraction of the particles, neglecting the 
specific impact of submicron/nano-sized particles which have been otherwise shown to be 
reactive and able to induce biological effects. To fill this gap, we previously developed an 
innovative protocol to isolate micron-sized particles from submicron/nano-sized particles 
contained in 100 broncho-alveolar lavages (BAL) and bronchial washes (BW) from patients 
who suffered from interstitial lung diseases (ILD) (NanoPI, ClinicalTrials.gov Identifier: 
NCT02549248). We then determined qualitatively and quantitatively the metal load in each of 
these fractions. The aim of the present paper is to investigate correlations between these 
mineralogical analyses and clinical data. The mean concentration of submicron silica particles 
was found to be significantly higher in BAL and BW from patients suffering from sarcoidosis 
than in patients suffering from other ILD (501 vs 246 ng/mL BAL and 564 vs 292 ng/mL BW 
respectively). This finding suggests a potential role of submicron silica particles in the 
etiology of sarcoidosis and highlights the usefulness of comprehensive mineralogical analyses 
to get new insights in the role of inhaled biopersistent particles in lung diseases.  
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Introduction 
Mineralogical analyses of clinical samples using electron or optical microscopy have been 
proven useful to identify a causal relationship between exposure to inhaled microparticles and 
pulmonary diseases 1. Thus, the quantification of biopersistent particles can provide new 
insights in the role of inhaled particles in the etiology or development of some respiratory 
diseases 2. It is perfectly exemplified by asbestosis where the assessment of asbestos bodies in 
patient lung tissues or in broncho-alveolar lavages (BAL) has allowed the definition of 
threshold values specific of diseases 3. However, this type of mineralogical analyses only 
considers the micron-sized fraction of the particles, neglecting the specific impact of 
nanoparticles and submicron particles which have been otherwise shown to be reactive and 
with the ability to induce biological effects. This is partly explained by the technical 
challenges associated to these analyses 4. To fill this gap, we specifically developed an 
innovative experimental protocol to isolate micron-sized particles from submicron/nano-sized 
particles, in order to separately analyze these fractions 5,6. To illustrate the pathological 
relevance of mineralogical analyses, we investigated relationships between metal loads in 
patient BAL and clinical data with a particular emphasis on sarcoidosis 6.  
Sarcoidosis is a multisystem inflammatory disease of undetermined etiology 7–10. It is 
characterized by the formation of granulomas in various organs, mainly the lungs and the 
lymphatic system 7,9,10. Although the exact causative agent of sarcoidosis is still unknown, it 
is commonly acknowledged that this disease results from an exaggerated immune response to 
one or more unidentified antigens in individuals who are genetically susceptible 7,9. The 
antigens have been proposed to be either of bacterial origin (especially mycobacteria and 
propionibacteria) or environmental factors, particularly if individuals are exposed to organic 
and inorganic particulates able to trigger inflammation 9,11. The assumption that sarcoidosis is 
an antigen-driven disease is further supported by the fact that other granulomatous disorders 
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induced by known antigens, such as berylliosis (chronic beryllium disease), exhibit very 
similar pathological and clinical features 12,13. Similarly, talc pneumoconiosis can mimic and 
thus be confused with sarcoidosis 14–16. Progress in the diagnosis and prevention of 
sarcoidosis is expected from the identification of the exact causes of this disease 9,10. 
The contribution of inorganic particulates to sarcoidosis has long been suggested. In 
particular, nanoparticles are increasingly suspected to trigger granuloma formation 11,17–20. A 
relationship between exposure to inhaled nanoparticles and long-term negative effects in 
humans has been suggested by Song et al. 21,22. They reported the case of seven women who 
developed important lung symptoms after being exposed for several months to airborne 
polyacrylate nanoparticles at their workplace. Most importantly, nanoparticles of the same 
raw materials the workers were exposed to in the plant (particularly silica nanoparticles and 
nano- and microscale silicates) were found in the patients’ tissue and effusions. However, the 
conclusion that silica nanoparticles were responsible for the pathological findings is only 
hypothetical as the patients had been exposed to other toxic substances; still, the study drew 
attention to silica nanoparticles as potential contributors to a lung disease. 
In this context, we performed an exploratory clinical study where we qualitatively and 
quantitatively assessed the metal load in 100 BAL from patients who suffered from interstitial 
lung diseases (ILD) and were in need of this invasive procedure for clinical purposes 6. The 
aim of the present paper is to determine if correlations can be found between metal loads and 
clinical data, allowing getting new insights in the etiology of some respiratory diseases. To 
the best of our knowledge, it is the first time such comprehensive mineralogical analyses are 
performed and correlated with clinical data. 
 
Materials and Methods 
Patients 
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During 2 years, 100 patients from the Chest diseases and thoracic oncology Department of the 
University Hospital of Saint-Etienne were included in a prospective, monocentric and 
exploratory study (NanoPI, ClinicalTrials.gov Identifier: NCT02549248). Patients presented a 
clinical image of diffuse ILD and needed a bronchoscopy associated with a BAL (i.e., this 
procedure was not performed on purpose for this study). All patients were informed about this 
study and had to give their written consent to participate. Our protocol was in accordance with 
ethical principles defined by the World Medical Association declaration of Helsinki and 
subsequent amendments and was approved by an ethics committee (Comité de Protection des 
Personnes, Sud-Est I) as well as by the French agency regulating biomedical research 
(Agence Nationale de Sécurité du Médicament et des produits de santé, ANSM).  
Criteria for the inclusion in the study were: i) patients with an interstitial lung disease 
assessed on clinical signs and CT scan, requiring a flexible bronchoscopy associated with a 
BAL (for instance for patients suffering from sarcoidosis, idiopathic pulmonary fibrosis, 
hypersensitivity pneumonitis, infectious or cancerous interstitial diseases and interstitial 
diseases caused by drug reactions), ii) patients older than 18, iii) patients who had given their 
voluntary, informed and written consent, iv) patients having a social insurance or beneficiary 
(mandatory for any French clinical study). Exclusion criteria were: i) patients who had not 
given their consent, ii) when flexible bronchoscopy or BAL was not possible, iii) patients 
under legal protection or pregnant women, iv) patients with contagious disease (e.g., HIV 
infection, tuberculosis, viral hepatitis) for safety reasons. 
 
Broncho-alveolar lavages 
BAL were performed following regular practice in the Chest diseases and thoracic oncology 
Department of the University Hospital of Saint-Etienne. Briefly, 50 mL of a warmed saline 
solution were injected in the selected area of lung and were slowly aspirated, the collected 
 
6 
 
sample constituting the bronchial wash (BW). Then, 2 to 4 additional 50 mL of warmed saline 
solution were injected and aspirated successively, the collected sample representing the BAL 
strictly speaking. All samples were collected into plastic tubes without any fixative agent. 
They were immediately transferred to the Histology-Cytology Department for standard 
cytological analysis. After this analysis, if there was still enough volume of sample 5 mL of 
BW and 20 mL of BAL were dedicated to the present study. An equivalent volume of sodium 
hypochlorite was added to the samples that were then stored at 4°C until use. 
 
Sample pre-treatment and analysis 
BAL and BW samples underwent a well-characterized and validated size fractionation 
protocol to separate microparticles (> 1 µm) from submicron particles (ranging from 100 nm 
to 1 µm) and nanoparticles and ions (particles < 100 nm). The method and its application have 
been described in detail in our previous publications 5,6. A summary of the protocol is 
provided as Supplementary information. All fractions were analyzed using both dynamic light 
scattering (DLS) method (Nanozetasizer®, Malvern Instrument) and inductively coupled 
plasma atomic emission spectroscopy (ICP-AES, Jobin-Yvon JY138 Ultrace). DLS allowed 
verifying that size fractionation was successful. ICP-AES allowed determining for each metal 
the quantity of matter expressed in parts-per-billion (ppb), i.e., as ng/mL. We focused our 
investigation on the following metals: aluminum (Al), beryllium (Be), cobalt (Co), chromium 
(Cr), copper (Cu), iron (Fe), nickel (Ni), silicon (Si), titanium (Ti), tungsten (W), zinc (Zn) 
and zirconium (Zr). To assess potential contamination from the particles present in the 
environment, the materials and solutions used, we used “blank” samples consisting of saline 
solution aspirated through the bronchoscope and placed in the same tubes as clinical samples, 
a filtered sodium hypochlorite solution (i.e. the solution in which the LBA were conditioned) 
was then added (volume to volume) and blank samples were processed and analyzed exactly 
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the same way as clinical samples were. Samples of interest were also observed using scanning 
electron microscopy coupled to an EDX detector (Energy-dispersive X-ray spectroscopy), as 
previously described 6.  
 
Comparison to clinical data 
We classified patients in two groups: patients suffering from sarcoidosis and patients 
suffering from other types of ILD. Details on the cohort are reported in Table 1. The diagnosis 
was obtained on biopsies showing bronchial or node non-necrotic granulomatous reaction and 
a typical CT scan pattern of peri-broncho-vascular micro-nodules. 13 patients presented a 
stage 2 sarcoidosis and 1 a stage 3. The clinical features of patients suffering from sarcoidosis 
are summarized in Table 2. 
 
Results 
We previously established a size fractionation protocol to separate microparticles from 
submicron particles and nanoparticles in patient pulmonary lavages and assessed the metal 
load in these fractions 5,6. In the present paper we explored how these physico-chemical 
results corresponded to clinical data. Specifically, we compared the metal load in BAL and 
BW samples from patients suffering from sarcoidosis and patients suffering from other ILD. 
Comprehensive results are reported in Supplementary information. As shown in Table 3, only 
submicron Si particles (both in BW and BAL), Si microparticles in BAL, and Al 
microparticles in BW seemed to have a differing presence in the two groups. However, only 
the difference in submicron Si particles reached statistically significant levels between the two 
groups (p<0.05, as calculated with a Mann-Whitney test).  
Figure 1 reports the detailed comparison for submicron Si particles concentration in BW and 
BAL in patients suffering either from sarcoidosis or other types of ILD.  
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Two assumptions could be made to explain the different medians between the sarcoidosis and 
other ILD groups. This difference could be due to either i) a different submicron Si particles 
concentration or ii) a different prevalence of patients with detectable submicron Si particles. 
To try to shed light on this aspect, we only considered pulmonary lavage fluids of which the 
Si concentration in the submicron particle fraction was higher than the limit of detection 
(LoD). We then determined the frequency of patients exhibiting a Si load higher than the LoD 
and we calculated the mean Si concentration in submicron particle fraction considering only 
these patients (see Table 4). From the results, we can confirm the second hypothesis. 
The size and the chemical nature of the extracted particles were verified using scanning 
electron microscopy coupled to an EDX analysis. Figure 2 is an illustration of submicron Si 
particles found in the BW from patient n°12. It is representative of what was observed in all 
patients suffering from sarcoidosis and exhibiting a Si concentration higher than the LoD in 
their submicron particle fraction as assessed with the ICP analysis. Conversely, we also 
verified with this technique that actually no submicron Si particles were found in the 2 
patients suffering from sarcoidosis who exhibited a null Si submicron particles concentration 
as assessed with the ICP analysis.  
 
Discussion  
Mineralogical analyses of patient pulmonary lavages that underwent a size-fractionation 
protocol allowed us to detect a significantly higher concentration of submicron Si particles in 
patients suffering from sarcoidosis than in patients suffering from another ILD (Table 3 and 
Figure 1). Although this finding has to be confirmed with further analysis of larger cohorts, it 
suggests a potential role of these particles in this disease. Of note, this correlation was 
observed only for particles in the submicron size range but not for bigger (i.e. micron-sized) 
particles. It confirms the observations from our previous study where we had not found any 
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clear correlation between the metal content of microparticle, submicron particle, and 
nanoparticle fractions of broncho-alveolar lavages 6. Thus, this finding further stresses the 
need to separately analyze particle populations of different sizes in order to achieve a more 
comprehensive mineralogical analysis. 
The other corollary of this finding is that it evidences the impact of the particle size on the 
pathogenesis of a disease. The toxicity of silica particles, especially crystalline silica, is not 
new and is well-documented 23. Please note that strictly speaking we assessed the silicon 
content of BAL and BW and further physico-chemical characterizations are necessary to 
better define the exact nature of the silicon-based particles identified. However, we can 
reasonably assume that due to its ubiquitous nature silica is the component we are mainly 
exposed to. A wide variety of diseases can be induced after silica inhalation ranging from 
acute lung inflammation to silicosis, but also lung fibrosis, cancer, emphysema, pulmonary 
tuberculosis, or autoimmune diseases, such as scleroderma (systemic sclerosis), rheumatoid 
arthritis, chronic renal disease, and lupus 23–26. Yet so far, little attention has been paid to the 
specific impact of the particle size on human health effects associated with silica exposure. In 
the context of mineralogical analyses, this can be mainly explained by the technical 
challenges one has to face in order to separately analyze differentially sized particle 
populations, as we have already demonstrated 2,4. However, despite some inconsistencies, in 
vitro and in vivo studies brought interesting data on the toxicity of nano-sized silica 25. 
Nanoparticles are characterized by specific physico-chemical features, very distinct from 
those of their bulk form. They confer on them enhanced properties for many applications. 
More particularly, they are characterized by an increased surface-to-volume ratio and a higher 
surface reactivity 25. It seems therefore logical that they could trigger different adverse effects 
than larger particles 20,25. In addition, due to their small size they can translocate across 
barriers of the body (such as the air-blood barrier), enter the circulation, and interact with 
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various organs 25. As an example, a recent study from Kreyling et al. 27 investigated the 
deposition patterns of inhaled 20 nm gold nanoparticles in rats and their biokinetics. They 
observed that about 30% of the nanoparticles were deposited on airway epithelia and rapidly 
cleared by mucociliary clearance. About 80% of the nanoparticles deposited in the alveoli was 
relocated from the epithelium into the interstitium within 24h. Re-entrainment within 
macrophages back to the lung epithelium and to the larynx and gastro-intestinal tract occurred 
and were responsible for nanoparticle clearance. Translocation across the air-blood-barrier led 
to persistent retention in secondary organs and tissues such as liver, soft tissue, spleen, etc. 
However, translocation, as well as the biological effects induced by the particles, do not 
depend only on the particle size. Indeed, many factors may play a role such as the shape, 
surface chemistry, surface charge, etc. 28,29. Furthermore, for a same material, a 5 nm, a 20 nm 
or a 80 nm particle (all considered as nanoparticles) can exhibit very different biological 
behavior and thus trigger very different biological responses. Therefore, the relationship 
between translocation, particle size and pathogenicity is not as simple as that and it requires 
further studies to better understand if indeed (and if necessary why) nanoparticles are less 
important for the pathogenesis of sarcoidosis than submicron particles.  
The results of our advanced mineralogical analyses led us to propose a potential role of 
submicron silica particles in the pathogenesis of sarcoidosis. This assumption makes sense if 
we consider the clinical manifestations of the disease. Indeed, although it can affect any 
organ, more than 90% of cases involve the lungs which are affected first, arguing in favor of 
an inhaled antigen 10. As a matter of fact, inhaled antigens first deposit in the lungs where 
they can locally trigger granulomas. Then, due to their small size, nanoparticles and 
submicron-sized particles are able to cross the alveolo-capillary barrier, reach the blood 
and/or lymph circulation and be distributed to different distant organs where they can also 
induce granulomas 17,20,30. The specific size of these particles could also explain why 
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submicron silica particles have not been involved so far. Indeed, to the best of our knowledge, 
very few studies focus on the biomonitoring of inhaled nanoparticles in human biological 
samples 2 and when they do, the mineralogical analysis is performed on whole samples, i.e. 
without separating the bigger particles from the smaller ones. As mentioned before, it results 
in a partial view and the specific effects of the submicron particles cannot be adequately 
assessed 6.  
Furthermore, our claim that submicron silica particles could be a causative agent of 
sarcoidosis, or at least an adjuvant signal, is consistent with many data reported in the 
literature. Indeed, correlations have been established between sarcoidosis and both 
environmental and occupational exposure, especially metal industry and intense agriculture 
through exposure to insecticides or to microbial bioaerosols in work environments with 
mold/mildew exposures 8,11,13,31. Regarding this issue, of particular interest is the study from 
Deubelbeiss et al. 13 which aimed at investigating the incidence, prevalence and regional 
distribution of sarcoidosis in Switzerland with respect to environmental exposures. It clearly 
demonstrated that the regional workforce in the metal industry, water supply, air transport 
factories and the area of potato production, artificial meadows (grassland) and bread grains 
were positively associated with the frequency of sarcoidosis. Positive correlations between 
sarcoidosis and exposure to dust are also unfortunately illustrated by the studies on the World 
Trade Center responders who exhibit elevated rates of sarcoidosis, higher than in the rest of 
the population 8,11. Newman and Newman 11 proposed a slightly different contribution of 
inorganic particulates to the sarcoidosis pathogenesis. They suggested that exposure to 
inorganic particles promotes the inflammatory context necessary for the development of an 
excessive granulomatous immune response to a number of different antigens. Anyway, the 
role of fine particulates in this pathology is experiencing a growing interest. And our finding 
brings an additional argument in favor of an environmental factor. 
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Regarding the mean age of the patients (Table 1), we observed that it was lower in the 
sarcoidosis group (where submicron Si particles concentration was higher) than in the other 
ILD group (where Si particles concentration was lower), suggesting that Si deposition in the 
lungs is not necessarily related to the patient age. This observation strengthens our hypothesis 
that submicron Si particles may be involved in the onset or development of sarcoidosis. 
Similarly, the smoking status doesn’t seem to play a key role as it is similar between the two 
groups: 14% and 12% for sarcoidosis and other ILD respectively. 
When all patients were considered (Table 3 and Figure 1), we found different median and 
mean submicron silica particle concentrations between patients suffering from sarcoidosis and 
patients suffering from other ILD. But when we considered only the patients exhibiting a 
positive submicron silica particle concentration (i.e., concentrations higher than the LoD, 
Table 4) we observed no statistically significant difference. However, the frequency of the 
submicron silica particle presence was much higher in patients suffering from sarcoidosis 
(Table 4). It is consistent with the fact that a genetic susceptibility is necessary to develop the 
disease, and it could explain why out of two individuals exhibiting a similar submicron silica 
particle concentration, only one could develop the disease. Still, we must be very cautious in 
the interpretation of this finding and we should keep in mind that a higher concentration of 
submicron silica particles in pulmonary lavages from patients suffering from sarcoidosis is 
not an evidence of causality. It just suggests that the lung biopersistence of these submicron 
silica particles may be involved, one way or another, in the pathogenesis of this disease. To 
develop sarcoidosis three conditions must be met: exposure to one or more antigens, a 
favorable genetic background, and a hyper-reactive immune system 7,9,10. Further studies are 
necessary to investigate more deeply the potential role of inhaled, submicron silica particles in 
sarcoidosis. Indeed, this work is an observatory study and from our finding we can now focus 
on this disease and these specific particles and carry out further physico-chemical 
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characterizations to sharpen our conclusions and better define some features such as the origin 
or the crystalline/amorphous nature of the silica particles identified. It should be especially 
interesting to combine advanced mineralogical analyses to in vitro / in vivo studies so as to 
precisely determine if these particles are able to trigger biological effects and by which 
mechanisms as previously suggested 2,17.  
 
Conclusion  
We suggest that inhaled, submicron silica particles could have a role in the development of 
sarcoidosis and present an additional argument in favor of an environmental factor involved 
in the etiology of this disease. This specific case underscores the relevance of mineralogical 
analyses including the micro to nano-sized fractions towards a better understanding of the 
development of some respiratory diseases. It opens new perspectives in the clinical 
nanotoxicology field. 
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Figure captions 
 
Figure 1 – Submicron Si particles concentration in BW and BAL of patients suffering either 
from sarcoidosis or another type of ILD. The median (in bold), minimal and maximal values, 
as well as the first and third quartiles are indicated. The number of patients from each group is 
reported in parentheses (please note that due to technical reasons 7 BW and 6 BAL samples 
could not be analyzed). 
 
Figure 2 – Submicron Si particles detected in the BW from patient n°12 using scanning 
electron microscope coupled to an EDX detector. 
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Figure 1 
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Figure 2 
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Table 1 – Description of the cohort. 
Disease Number of  
patients 
Mean age  
[min-max] 
Sex ratio  
(M:F) 
Smokers  
(former smokers) 
Sarcoidosis 14 53 [28-85] 6:8 14% (7%) 
Other ILD: 
Idiopathic nonspecific interstitial pneumonia 
Idiopathic pulmonary fibrosis 
Drug related ILD 
Infectious ILD 
Hypersensitivity pneumonitis 
Auto-immune pneumonitis 
Lymphangitis carcinomatosis /Neoplasia 
Desquamative interstitial pneumonia 
Pneumoconiosis 
Pulmonary veno-occlusive disease 
Silicosis 
Microscopic polyangiitis  
Granulomatosis with polyangitis (Wegener’s granulomatosis) 
Left heart failure  
Lipoid pneumonia 
Bronchiolitis obliterans 
Antisynthetase syndrome 
Others 
86 
11 
9 
15 
12 
7 
5 
4 
3 
2 
2 
1 
1 
1 
1 
1 
1 
2 
8 
72 [27-91] 62:24 12% (42%) 
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Table 2 – Clinical features of the patients suffering from sarcoidosis. Please note that it was impossible to perform the BAL for patient n°2, only 
BW was obtained for this patient. All patients are Caucasian except patient n°11 who is black. GI: non necrotic granulomatous inflammation, 
MDD: multi-disciplinary discussion, EBUS: Endo-bronchial ultra-sound, TBNA: transbronchial needle aspiration, Neg: negative. * indicates the 
cases of multi-organ sarcoidosis. 
Patient Gender Age Smoker Occupation(s) 
% 
lymphocytes 
in BAL 
CT scan Diagnostic tools 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
 
12 
13 
14 
F 
F 
F 
M 
F 
F 
F 
M 
F 
M 
M 
 
F 
M 
M 
59 
69 
64 
79 
44 
44 
69 
48 
52 
37 
43 
 
27 
25 
24 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
 
No 
No 
Yes 
Seamstress, industrial cleaning (wood), housekeeping 
Farming 
Seamstress, housekeeping, childminder, library assistant 
Serviceman, druggist, accountant 
Animator (retirement home) 
Industrial cleaning 
Secretary, police 
Drilling (stone quarry), machine operator, public works 
Homecare assistant 
Masonry, Serviceman (Paris firefighter) 
Electrician, agro-food company, metallurgy, automobile 
industry 
Controller (train), music teacher 
Electrician, salesman 
Plasterer, painter, masonry, mover, mechanic industry, 
serviceman, greengrocer 
58 
- 
86 
83 
30 
15 
50 
7 
33 
32 
34 
 
32 
39 
14 
Stage II 
Stage II 
Stage II 
Stage III 
Stage II 
Stage II 
Stage II 
Stage II 
Stage II 
Stage II 
Stage II 
 
Stage II 
Stage II 
Stage II 
GI on bronchial biopsies and EBUS TBNA 
GI on lung biopsies, mediastinal nodes and bone marrow*  
GI on mediastinal lymph nodes (mediastinoscopy) 
CD4 alveolitis, ACE elevated, lung biopsies refused, diagnosis validated by MDD 
GI on bronchial biopsies and EBUS TBNA (4R,7, 11R), Loefgren syndrome 
Neg. bronchial biopsies, ACE elevated, typical CT scan, initial Loefgren syndrome 
GI on mediastinoscopy + ENT lesions* 
ACE elevated, specific uveitis, diagnosis validated by MDD* 
Neg. EBUS and mediastinoscopy, diagnosis validated by MDD 
GI on bronchial biopsies 
GI on transbronchial biopsies and conventional TBNA, sytemic involvement: 
ENT, skin, liver*  
GI on bronchial biopsies 
GI on bronchial biopsies, initial Loefgren syndrome 
GI on bronchial biopsies 
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Table 3 – Comparison of the median and mean concentration of Si and Al microparticles and 
submicron particles in BW and BAL of patients suffering either from sarcoidosis or another 
type of ILD. p calculated with a Mann-Whitney test. Differences are considered significant 
when p<0.05 and are indicated in bold. 
 
Median Mean 
Sarcoidosis Other ILD Sarcoidosis Other ILD 
Submicron Si particles 
concentration in BW (ppb) 
581.5 159.8 564.2 ± 442.7 292 ± 385.2 
p = 0.017 
Submicron Si particles 
concentration in BAL (ppb) 
320.4 159.3 501.2 ± 399.4 246.2 ± 342.1 
p = 0.022 
Si microparticles 
concentration in BAL (ppb) 
0 0 247.4 ± 279.5 92.3 ± 198.5 
p = 0.242 
Al microparticles 
concentration in BW (ppb) 
186 0 151.8 ± 121.9 109.2 ± 191.2 
p = 0.254 
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Table 4 – Mean Si concentration in the submicron particle fraction extracted from pulmonary 
lavage fluids of patients at levels higher than the limit of detection (LoD). The number of 
patients exhibiting Si concentration higher than the LoD is also indicated. A Mann-Whitney 
test was performed to investigate statistically significant differences of Si concentration 
between the sarcoidosis and other ILD groups; ns means not significant.  
 
BW BAL 
Sarcoidosis Other ILD Sarcoidosis Other ILD 
Mean Si submicron particles 
concentration ± SD (ppb)  
658.28 ± 405.11 549.28 ± 370.83 529.37 ± 363.35 463.86 ± 345.75 
ns ns 
Prevalence of patients with 
detectable Si submicron 
particles 
12/14 
86% 
42/79 
53% 
11/13 
85% 
43/81 
53% 
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Supplementary information 
 
1. Details on the sample pre-treatment for the separation of the micro, sub-micro and 
nano/ion fractions  
The process developed for particle size fractionation consists of a 2 step-centrifugation. The 
first centrifugation was short and allowed to separate the fraction containing microparticles 
from the fraction containing sub-micro and nano-sized particles and potentially soluble metals 
(ions). The second centrifugation, longer than the first one, allowed separating sub-
microparticles from nanoparticles and ions.  
Step 1: isolation of the “micro” fraction – Samples were vortexed and sonicated using a 
Branson sonicator and Cup Horn (70%, 2 min at room temperature). 1 mL of sample was 
transferred into a 2 mL Protein LoBind tube (Eppendorf). 0.5 mL of an extraction cushion 
consisting of a glycerol 75%v/v, NaOH 0.001 M 25%v/v solution was added to the samples. 
Because of their difference of density, the sample and the glycerol solution did not mixed. 
The tubes were centrifuged 10 min at 0°C, 1600g (4000 rpm) (Thermo Fisher Scientific 
Heraeus megafuge 16R). Tubes were then punctured at the level of the 0.25 mL mark with a 
needle (22G x 11/2 Terumo©) mounted on a 2 mL syringe and the supernatant was aspirated 
and transferred into a new Protein LoBind tube, this part contained the sub-microparticles, 
nanoparticles and ions ( 1.25 mL). The pellet containing the microparticles was resuspended 
with 0.75 mL of NaOH 0.001 M and was transferred into a new Protein LoBind tube and 
stored at 4°C until analysis. 
Step 2: separation of the “sub-micro” fraction from nano and ions – 0.5 mL of an extraction 
cushion (glycerol 75%v/v, NaOH 0.001 M 25%v/v) was added to the tube containing the sub-
microparticles, nanoparticles and ions fractions obtained from step 1. Tubes were centrifuged 
during 3h30 at 0°C, 2500 g (5000 rpm). Tubes were then punctured at the 0.5 mL mark with a 
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needle (22G x 11/2 Terumo©) mounted on a 2 mL syringe and the supernatant was slowly 
aspirated and transferred into a new Protein LoBind tube, this part contained nanoparticles 
and ions. The pellet containing the sub-microparticles was resuspended with 0.6 mL of NaOH 
0.001 M and was transferred into a new Protein LoBind tube and stored at 4°C until analysis. 
To assess the background noise a “blank” sample consisting of distilled water underwent the 
same protocol. 
 
 
2. Comprehensive results of the mineralogical analyses 
In Tables S1 to S12 are reported the mean concentrations observed for each element in the 
micron, submicron and nano/ion fractions for BW and BAL. 
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Table S1 - Mean Al concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 152 ± 122 18 ± 26 55 ± 132 0 11 ± 11 3 ± 4 
Other ILD: 86 109 ± 191 8 ± 17 28 ± 101 38 ± 129 5 ± 9 2 ± 3 
Idiopathic nonspecific interstitial pneumonia 11 274 ± 433 24 ± 37 127 ± 249 0 7 ± 10 2 ± 3 
Idiopathic pulmonary fibrosis 9 23 ± 68 0 2 ± 3 51 ± 101 0 2 ± 3 
Drug related ILD 15 103 ± 134 8 ± 17 24 ± 79 80 ± 118 5 ± 8 2 ± 3 
Infectious ILD 12 150 ± 144 12 ± 16 27 ± 81 0 11 ± 11 2 ± 3 
Hypersensitivity pneumonitis 7 148 ± 139 11 ± 9 15 ± 31 0 10 ± 10 2 ± 3 
Auto-immune pneumonitis 5 0 0 3 ± 3 196 ± 437 0 0 
Lymphangitis carcinomatosis /Neoplasia 4 137 ± 137 11 ± 11 54 ± 80 58 ± 100 10 ± 10 5 ± 3 
Desquamative interstitial pneumonia 3 58 ± 101 0 2 ± 4 0 0 0 
Pneumoconiosis 2 0 0 3 ± 4 0 0 6 ± 0 
Pulmonary Pulmonary veno-occlusive disease 2 0 0 0 0 0 0 
Silicosis 1 290 19 7 0 25 0 
Microscopic polyangiitis 1 0 0 0 0 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 0 0 0 7 
Left heart failure 1 0 0 0 0 0 0 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 0 0 0 
Antisynthetase syndrome 2 235 ± 68 11 ± 16 3 ± 4 0 10 ± 14 0 
Others 8 62 ± 124 0 1 ± 3 58 ± 116 2 ± 4 1 ± 3 
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Table S2 - Mean Be concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 0 0 ± 1 0 0 0 10 ± 35 
Other ILD: 86 0 0 ± 1 0 ± 1 0 0 6 ± 26 
Idiopathic nonspecific interstitial pneumonia 11 0 0 0 0 0 0 
Idiopathic pulmonary fibrosis 9 0 0 ± 1 0 0 0 0 
Drug related ILD 15 0 0  0 ± 1 0 0 ± 1 17 ± 45 
Infectious ILD 12 0 0 ± 1 0 ± 1 0 0 0 
Hypersensitivity pneumonitis 7 0 1 ± 2 0 0 0 32 ± 54 
Auto-immune pneumonitis 5 0 1 ± 1 0 0 0 0 
Lymphangitis carcinomatosis /Neoplasia 4 0 2 ± 2 2 ± 4 0 0 8 ± 14 
Desquamative interstitial pneumonia 3 0 0 0 0 0 0 
Pneumoconiosis 2 0 0 0 0 0 0 
Pulmonary veno-occlusive disease 2 0 0 0 0 0 0 
Silicosis 1 0 0 0 0 0 0 
Microscopic polyangiitis 1 0 0 0 0 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 0 0 0 0 
Left heart failure 1 0 0 0 0 0 0 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 0 0 0 
Antisynthetase syndrome 2 0 0 0 0 0 0 
Others 8 0 0 0 0 0 0 
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Table S3 - Mean Co concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 0 1 ± 1 1 ± 2 0 0 ± 1 0 
Other ILD: 86 0 ± 3 1 ± 2 0 ± 1 0 0 ± 1 0 
Idiopathic nonspecific interstitial pneumonia 11 0 1 ± 2 0 0 0 0 
Idiopathic pulmonary fibrosis 9 0 0 ± 1 0 0 1 ± 1 0 
Drug related ILD 15 1 ± 2 1 ± 2 0 ± 1 0 0 ± 1 0 ± 1 
Infectious ILD 12 0 1 ± 2 1 ± 1 0 1 ± 1 0 
Hypersensitivity pneumonitis 7 0 1 ± 3 0 ± 1 0 0 ± 1 0 
Auto-immune pneumonitis 5 0 1 ± 1 0 0 0 0 
Lymphangitis carcinomatosis /Neoplasia 4 6 ± 10 0 ± 1 2 ± 3 0 1 ± 1 0 
Desquamative interstitial pneumonia 3 0 0 ± 1 0 0 0 0 
Pneumoconiosis 2 0 0 0 0 1 ± 1 0 
Pulmonary veno-occlusive disease 2 0 0 0 0 0 0 
Silicosis 1 0 0 0 0 0 0 
Microscopic polyangiitis 1 0 0 0 0 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 0 0 0 0 
Left heart failure 1 0 0 0 0 0 0 
Lipoid pneumonia 1 0 1 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 0 0 0 
Antisynthetase syndrome 2 0 1 ± 1 0 0 0 0 
Others 8 0 0 ± 1 0 0 0 ± 1 0 
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Table S4 - Mean Cr concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 1 ± 1 15 ± 5 13 ± 2 0 ± 1 12 ± 1 13 ± 1 
Other ILD: 86 0 13 ± 2 13 ± 3 0 ± 1 12 ± 1 12 ± 2 
Idiopathic nonspecific interstitial pneumonia 11 0 13 ± 1 13 ± 2 0 13 ± 0 13 ± 1 
Idiopathic pulmonary fibrosis 9 0 13 ± 3 11 ± 4 0 12 ± 1 13 ± 0 
Drug related ILD 15 0 ± 1 13 ± 1 13 ± 1 0 12 ± 2 12 ± 1 
Infectious ILD 12 0 13 ± 3 13 ± 3 0 12 ± 1 13 ± 1 
Hypersensitivity pneumonitis 7 0 14 ± 4 13 ± 2 0 11 ± 2 11 ± 5 
Auto-immune pneumonitis 5 0 ± 1 13 ± 1 13 ± 1 0 12 ± 1 12 ± 1 
Lymphangitis carcinomatosis /Neoplasia 4 0 15 ± 2 17 ± 6 0 12 ± 0 13 ± 1 
Desquamative interstitial pneumonia 3 0 12 ± 1 13 ± 0 0 12 ± 1 12 ± 1 
Pneumoconiosis 2 0 11 ± 1 13 ± 0 0 13 ± 0 14 ± 1 
Pulmonary veno-occlusive disease 2 0 13 ± 0 12 ± 0 0 13 ± 0 12 ± 1 
Silicosis 1 0 12 11 0 13 14 
Microscopic polyangiitis 1 0 10 14 0 13 14 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 11 11 0 12 13 
Left heart failure 1 0 10 12 0 12 13 
Lipoid pneumonia 1 0 12 13 0 11 12 
Bronchiolitis obliterans 1 0 13 12 5 13 13 
Antisynthetase syndrome 2 0 13 ± 1 12 ± 1 0 13 13 
Others 8 0 12 ± 1 13 ± 1 0 13 ± 0 12 ± 1 
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Table S5 - Mean Cu concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 7 ± 14 83 ± 151 9 ± 14 2 ± 8 3 ± 7 0 
Other ILD: 86 3 ± 8 13 ± 51 3 ± 9 8 ± 16 3 ± 7 0 ± 2 
Idiopathic nonspecific interstitial pneumonia 11 4 ± 12 9 ± 12 7 ± 13 12 ± 17 4 ± 9 0 
Idiopathic pulmonary fibrosis 9 0 0 0 13 ± 20 0 0 
Drug related ILD 15 5 ± 13 5 ± 10 4 ± 9 5 ± 15 1 ± 5 0 
Infectious ILD 12 0 7 ± 10 3 ± 8 12 ± 20 6 ± 9 1 ± 5 
Hypersensitivity pneumonitis 7 7 ± 12 61 ± 147 6 ± 12 7 ± 11 2 ± 7 0 
Auto-immune pneumonitis 5 1 ± 2 0 0 10 ± 13 0 0 
Lymphangitis carcinomatosis /Neoplasia 4 1 ± 3 74 ± 88 14 ± 14 0 5 ± 9 0 
Desquamative interstitial pneumonia 3 0 0 0 0 0 0 
Pneumoconiosis 2 0 0 0 0 0 0 
Pulmonary veno-occlusive disease 2 0 0 0 13 ± 19 0 0 
Silicosis 1 0 19 0 0 17 0 
Microscopic polyangiitis 1 0 0 0 28 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 0 0 0 0 
Left heart failure 1 0 0 0 53 0 0 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 0 0 0 
Antisynthetase syndrome 2 0 9 ± 12 8 ± 11 0 12 ± 16 0 
Others 8 7 ± 15 0 0 0 0 0 
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Table S6 - Mean Fe concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 48 ± 52 26 ± 19 177 ± 196 18 ± 34 4 ± 6 5 ± 7 
Other ILD: 86 32 ± 109 21 ± 69 62 ± 211 42 ± 80 14 ± 23 22 ± 82 
Idiopathic nonspecific interstitial pneumonia 11 8 ± 24 13 ± 5 29 ± 18 36 ± 56 14 ± 20 10 ± 11 
Idiopathic pulmonary fibrosis 9 20 ± 41 8 ± 6 18 ± 12 22 ± 44 11 ± 17 5 ± 6 
Drug related ILD 15 68 ± 230 12 ± 9  23 ± 18 18 ± 37 9 ± 6 10 ± 7 
Infectious ILD 12 30 ± 43 12 ± 7 30 ± 25 28 ± 39 10 ± 8 14 ± 21 
Hypersensitivity pneumonitis 7 11 ± 29 7 ± 7 9 ± 10 24 ± 41 5 ± 8 4 ± 7 
Auto-immune pneumonitis 5 14 ± 31 5 ± 7 3 ± 7 77 ± 125 7 ± 10 5 ± 7 
Lymphangitis carcinomatosis /Neoplasia 4 15 ± 25 15 ± 4 54 ± 23 19 ± 34 12 ± 7 7 ± 7 
Desquamative interstitial pneumonia 3 0 4 ± 7 7 ± 6 0 10 ± 1 13 ± 2 
Pneumoconiosis 2 0 7 ± 9 15 ± 22 33 ± 47 11 ± 16 13 ± 18 
Pulmonary veno-occlusive disease 2 70 ± 99 27 ± 22 6 ± 8 266 ± 248 46 ± 44 15 ± 0 
Silicosis 1 158 615 1745 73 15 16 
Microscopic polyangiitis 1 69 53 383 105 56 489 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 275 89 360 377 131 562 
Left heart failure 1 70 70 50 122 115 17 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 200 0 0 
Antisynthetase syndrome 2 0 18 ± 25 114 ± 162 38 ± 54 9 ± 13 0 
Others 8 0 17 ± 22 147 ± 259 18 ± 36 6 ± 7  6 ± 7 
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Table S7 - Mean Ni concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 3 ± 8 9 ± 18 0 0 0 0 
Other ILD: 86 3 ± 7 1 ± 6 0 0 0 0 
Idiopathic nonspecific interstitial pneumonia 11 2 ± 7 0 0 0 0 0 
Idiopathic pulmonary fibrosis 9 2 ± 6 0 0 0 0 0 
Drug related ILD 15 3 ± 8 0 0 0 0 0 
Infectious ILD 12 2 ± 6 0 0 0 0 0 
Hypersensitivity pneumonitis 7 3 ± 8 6 ± 16 0 0 0 0 
Auto-immune pneumonitis 5 0 ± 1 0 0 0 0 0 
Lymphangitis carcinomatosis /Neoplasia 4 1 ± 1 9 ± 15 0 0 0 0 
Desquamative interstitial pneumonia 3 9 ± 15 0 0 0 0 0 
Pneumoconiosis 2 0 0 0 0 0 0 
Pulmonary veno-occlusive disease 2 0 0 0 0 0 0 
Silicosis 1 0 0 0 0 0 0 
Microscopic polyangiitis 1 0 0 0 0 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 17 0 0 0 0 0 
Left heart failure 1 0 0 0 0 0 0 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 22 0 0 0 0 0 
Antisynthetase syndrome 2 0 0 0 0 0 0 
Others 8 0 0 0 0 0 0 
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Table S8 - Mean Si concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 279 ± 226 564 ± 443 0 247 ± 280 501 ± 399 0 
Other ILD: 86 205 ± 257 292 ± 385 10 ± 92 92 ± 199 246 ± 342 0 
Idiopathic nonspecific interstitial pneumonia 11 168 ± 165 457 ± 489 0 143 ± 250 347 ± 411 0 
Idiopathic pulmonary fibrosis 9 101 ± 151 90 ± 111 0 0 59 ± 88 0 
Drug related ILD 15 240 ± 381 211 ± 361 54 ± 210 39 ± 151 153 ± 304 0 
Infectious ILD 12 227 ± 191 487 ± 464 0 186 ± 259 426 ± 413 0 
Hypersensitivity pneumonitis 7 261 ± 244 499 ± 439 0 155 ± 265 382 ± 408 0 
Auto-immune pneumonitis 5 337 ± 312 127 ± 116 0 46 ± 103 141 ± 130 0 
Lymphangitis carcinomatosis /Neoplasia 4 427 ± 379 478 ± 478 0 246 ± 247 435 ± 439 0 
Desquamative interstitial pneumonia 3 181 ± 158 144 ± 125 0 0 138 ± 119 0 
Pneumoconiosis 2 180 ± 254 126 ± 178 0 0 110 ± 156 0 
Pulmonary veno-occlusive disease 2 0 0 0 0 0 0 
Silicosis 1 387 953 0 516 953 0 
Microscopic polyangiitis 1 298 231 0 0 205 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 166 0 0 153 0 
Left heart failure 1 0 153 0 0 160 0 
Lipoid pneumonia 1 317 199 0 0 209 0 
Bronchiolitis obliterans 1 0 0 0 0 0 0 
Antisynthetase syndrome 2 177 ± 250 493 ± 697 0 228 ± 322 465 ± 657 0 
Others 8 52 ± 104 51 ± 102 0 0 67 ± 133 0 
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Table S9 - Mean Ti concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 0 1 ± 2 8 ± 19 0 0 0 ± 1 
Other ILD: 86 3 ± 27 1 ± 2 4 ± 11 0 ± 2 0 ± 1 1 ± 1 
Idiopathic nonspecific interstitial pneumonia 11 26 ±79 2 ± 4 13 ± 25 0 0 1 ± 1 
Idiopathic pulmonary fibrosis 9 0 1 ± 1 1 ± 2 0 1 ± 2 1 ± 1 
Drug related ILD 15 0 1 ± 2 5 ± 13 0 0 1 ± 1 
Infectious ILD 12 0 ± 1 1 ± 2 3 ± 8 0 0 0 
Hypersensitivity pneumonitis 7 0 1 ± 1 2 ± 5 0 0 0 
Auto-immune pneumonitis 5 0 1 ± 2 1 ± 2 0 0 0 ± 1 
Lymphangitis carcinomatosis /Neoplasia 4 0 ± 1 1 ± 2 6 ± 7 0 0 1 ± 1 
Desquamative interstitial pneumonia 3 0 0 1 ± 1 0 0 1 ± 1 
Pneumoconiosis 2 0 0 0 9 ± 13 0 1 ± 1 
Pulmonary veno-occlusive disease 2 0 0 1 ± 2 0 0 1 ± 2 
Silicosis 1 0 0 0 0 0 0 
Microscopic polyangiitis 1 0 0 2 0 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 0 0 0 0 
Left heart failure 1 0 0 0 0 0 0 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 0 0 0 
Antisynthetase syndrome 2 0 0 1 ± 1 0 0 0 
Others 8 0 1 ± 2 1 ± 2 0 1 ± 1 1 ± 1 
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Table S10 - Mean W concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 2 ± 6 34 ± 83 0 1 ± 4 0 4 ± 14 
Other ILD: 86 3 ± 11 5 ± 25 0 6 ± 8 0 23 ± 117 
Idiopathic nonspecific interstitial pneumonia 11 0 3 ± 8 0 5 ± 7 0 6 ± 19 
Idiopathic pulmonary fibrosis 9 3 ± 10 0 0 4 ± 8 0 2 ± 7 
Drug related ILD 15 6 ± 17 16 ± 55 0 8 ± 10 0 77 ± 226 
Infectious ILD 12 5 ± 14 0 0 4 ± 7 0 52 ± 171 
Hypersensitivity pneumonitis 7 0 7 ± 18 0 3 ± 7 0 0 
Auto-immune pneumonitis 5 0 8 ± 19 0 6 ± 8 0 0 
Lymphangitis carcinomatosis /Neoplasia 4 4 ± 7 9 ± 15 0 0 0 0 
Desquamative interstitial pneumonia 3 0 0 0 4 ± 8 0 0 
Pneumoconiosis 2 0 0 0 9 ± 12 0 0 
Pulmonary veno-occlusive disease 2 0 0 0 18 ± 3 0 0 
Silicosis 1 0 0 0 0 0 0 
Microscopic polyangiitis 1 0 0 0 0 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 0 0 0 0 
Left heart failure 1 0 0 0 15 0 0 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 16 0 0 
Antisynthetase syndrome 2 0 0 0 9 ± 13 0 0 
Others 8 11 ± 23 0 0 14 ± 12 0 0 
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Table S11 - Mean Zn concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 10 ± 6 66 ± 127 19 ± 16 11 ± 2 5 ± 8 4 ± 5 
Other ILD: 86 7 ± 10 11 ± 50 10 ± 10 11 ± 4 2 ± 5 1 ± 3 
Idiopathic nonspecific interstitial pneumonia 11 7 ± 7 8 ± 14 16 ± 14 11 ± 3 4 ± 8 2 ± 4 
Idiopathic pulmonary fibrosis 9 8 ± 18 0 8 ± 6 10 ± 5 0 0 
Drug related ILD 15 8 ± 13 3 ± 9 8 ± 6 9 ± 5 2 ± 6 2 ± 3 
Infectious ILD 12 6 ± 6 5 ± 9 12 ± 9 13 ± 4 2 ± 6 1 ± 3 
Hypersensitivity pneumonitis 7 9 ± 4 47 ± 115 11 ± 13 11 ± 3 2 ± 6 1 ± 4 
Auto-immune pneumonitis 5 4 ± 7 0 6 ± 4 17 ± 9 0 0 
Lymphangitis carcinomatosis /Neoplasia 4 12 ± 8 80 ± 139 21 ± 14 9 ± 1 5 ± 6  2 ± 4 
Desquamative interstitial pneumonia 3 6 ± 5 0 3 ± 6 10 ± 1 0 0 
Pneumoconiosis 2 8 ± 11 0 3 ± 4 12 ± 3 0 0 
Pulmonary veno-occlusive disease 2 0 0 0 12 ± 1 0 0 
Silicosis 1 13 15 33 11 0 0 
Microscopic polyangiitis 1 9 0 13 17 0 8 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 8 12 0 0 
Left heart failure 1 0 0 0 11 0 0 
Lipoid pneumonia 1 0 0 0 11 0 0 
Bronchiolitis obliterans 1 0 0 7 11 0 0 
Antisynthetase syndrome 2 6 ± 9 3 ± 4 11 ± 3 10 0 0 
Others 8 8 ± 15 0 10 ± 7 9 ± 6 0 0 
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Table S12 - Mean Zr concentration ± standard deviation (ppb). 
Disease 
Number 
of 
patients 
BW BAL 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Micro 
particles 
Submicron 
particles 
Nanoparticles/ 
Ion 
Sarcoidosis 14 0 ± 1 4 ± 8 0 0 0 0 
Other ILD: 86 1 ± 7 2 ± 5 2 ± 12 0 1 ± 4 2 ± 12 
Idiopathic nonspecific interstitial pneumonia 11 0 4 ± 8 0 0 0 0 
Idiopathic pulmonary fibrosis 9 0 1 ± 1 1 ± 2 0 2 ± 5 0 
Drug related ILD 15 0 2 ± 4 3 ± 9 0 1 ± 1 8 ± 27 
Infectious ILD 12 5 ± 18 2 ± 6 1 ± 3 0 0 ± 1 1 ± 3 
Hypersensitivity pneumonitis 7 0 3 ± 7 15 ± 39 0 0 0 
Auto-immune pneumonitis 5 2 ± 2 2 ± 5 1 ± 3 0 1 ± 1 0 
Lymphangitis carcinomatosis /Neoplasia 4 0 10 ± 11 0 0 10 ± 15 0 
Desquamative interstitial pneumonia 3 0 0 0 0 0 0 
Pneumoconiosis 2 3 ± 4 0 0 0 0 0 
Pulmonary veno-occlusive disease 2 0 0 0 0 0 0 
Silicosis 1 0 0 0 0 0 0 
Microscopic polyangiitis 1 0 0 0 0 0 0 
Granulomatosis with polyangitis (Wegener’s granulomatosis) 1 0 0 0 0 0 0 
Left heart failure 1 0 0 0 0 0 0 
Lipoid pneumonia 1 0 0 0 0 0 0 
Bronchiolitis obliterans 1 0 0 0 0 0 0 
Antisynthetase syndrome 2 0 0 0 0 0 0 
Others 8 0 1 ± 1 0 0 1 ± 1 0 
 
 
